- Trial phase
- Phase 1a/1b completed; Phase II (MPox and Ebola) approved but not yet enrolling
- Time to market
- Unknown, likely 3-5+ years. The drug is in early Phase II for rare-disease indications (MPox, Ebola) with enrollment not yet started. Even if Phase II trials succeed, Phase III trials and regulatory filings would follow, and the company has limited financial resources to fund this timeline.
- Why 4/10
- No single hard, dated binary catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months. The next catalysts are Phase II trial initiations for MPox and Ebola in DRC (regulatory approvals obtained, enrollment not yet started) and potential interim data, these are incremental, not binary. The drug is the company's lead asset but impactScore is capped at 4 per the rubric for a Phase I-completed drug with no imminent regulatory decision.
Watch for Phase II enrollment updates for NV-387 in MPox (DRC) and Ebola (DRC), these trial starts are the next catalysts but lack hard binary dates. The company's heavy reliance on equity financing (ATM program, multiple registered directs in 2026) means ongoing dilution risk; monitor cash runway disclosures in upcoming SEC filings.
Price Chart
Executive Summary
NV-CoV-2 (API NV-387) is NanoViricides' lead broad-spectrum antiviral nanomedicine candidate, designed to neutralize multiple virus types by mimicking a host-cell surface feature. The drug completed Phase 1a/1b clinical trials in healthy volunteers with a clean safety profile (no adverse events across 36 subjects). The company has since pivoted from COVID-19 toward rare-disease indications, receiving regulatory approvals in the DRC for Phase II trials in both MPox and Ebola. However, NanoViricides has zero revenue, a sub-six-month cash runway, and has relied on multiple dilutive equity offerings (~$11.8M raised since late 2025) plus an ATM program and a high-interest CEO loan to fund operations. The stock trades at ~$1.33 with a mean analyst price target of $6.00 (7 Buy/Strong Buy ratings vs 1 Hold), but faces significant execution and financing risk with no near-term binary catalyst.
How It Works
NV-CoV-2 is a nanomedicine, a tiny polymer particle that acts like a 'molecular sponge' to trap and destroy virus particles. It mimics a feature on the surface of human cells (called sulfated proteoglycans) that many different viruses need to latch onto in order to infect cells. When a virus tries to use this decoy, it gets stuck to the nanomedicine instead of the real cells, neutralizing it. Because it targets a common viral attachment mechanism rather than a specific virus protein, it has the potential to work against many different viruses, coronaviruses, RSV, flu, MPox, and Ebola. It comes as an oral syrup or oral gummies.
Trial Status
Phase 1a (single-ascending dose) and Phase 1b (multiple-ascending dose) in 36 healthy volunteers completed successfully with no adverse events. Regulatory approval obtained from DRC authorities for Phase II trials in MPox (April 2026) and Ebola/Bundibugyo (August 2026), but patient enrollment and dosing have not yet commenced. The company has also discussed a potential adaptive respiratory 'basket' study for RSV/influenza in winter 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase II MPox trial initiation and first patient dosed in DRC
- Phase II Ebola trial initiation and first patient dosed in DRC
- Potential respiratory basket Phase II study for RSV/influenza (winter 2026)
- US FDA Orphan Drug Designation decision for MPox
- Quarterly SEC filings disclosing cash runway and dilution
- Potential interim Phase II data readouts (timing uncertain)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NANOVIRICIDES, INC. 424B5 NNVC ·Originating report